HUNTERBROOK
—
After inaccurate readings from Dexcom's flagship G7 device, some diabetics are ending up in the ICU - or dead.
Laura Wadsten
(She/Her)
As seen in:
HUNTERBROOK,
The Johns Hopkins News-Letter
Covers:
Antitrust, health care, pharmaceuticals, PBMs, insurance, drugs, corporate misconduct, greed, regulatory policy, litigation, FDA, CMS, HHS, anticompetitive conduct, consolidation, corporate power
investigating healthcare + pharma @hntrbrkmedia | former @Capitol_Forum @jhunewsletter | Minnesotan in DC
Laura Wadsten’s Journalist Portfolio
View as a gridLiquidia Drug Approved As Rival United Throws Hail Mary To Delay Actual Launch
HUNTERBROOK
—
7 lawsuits. 5 years. Millions of dollars. After Liquidia overcame each tactic that its nemesis United deployed to delay FDA approval, Liquidia was approved on May 23 to bring its new medicine Yutrepia to market.
Hims: Why The Semaglutide Shortage May End Imminently
HUNTERBROOK
—
The semaglutide shortage could be lifted any day, according to data analysis of past shortages on archived FDA webpages and interviews with industry experts.
Hims: Is Tomorrow the End of the GLP-1 Shortage?
HUNTERBROOK
—
Based on Hunterbrook Media's reporting, Hunterbrook Capital is short $HIMS at the time of publication. Positions may change at any time. See full disclosures below. By Thursday, the FDA will likely decide whether a key GLP-1 weight loss drug ingredient is still in shortage. The ruling will reshape the regulatory landscape and impact the future [...]
FDA Heads to Court to Defend Unprecedented Decision Protecting Lung Drug Monopoly From Liquidia C...
HUNTERBROOK
—
Litigation, IP, and medical experts told Hunterbrook that the saga highlights the hardball tactics Big Pharma uses to delay the launch of new medicines.
MTVA Unscripted :: Empowering the Move to Value Based Healthcare
www.movingtovalue.org
—
Podcast | The Moving to Value Alliance (MTVA) talks candidly and honestly with disruptors of the status quo in healthcare about the move to value-based care.
SPECIAL REPORT: Exclusive Drug Dealing - The Capitol Forum
The Capitol Forum
—
As part of our in-depth investigative reporting on the health care industry, The Capitol Forum recently launched our Exclusive Drug Dealing Project, which looks at price, market share and generic formulary exclusion data to spot anticompetitive conduct in the pharmaceutical supply chain.